Fisiopatologia da epilepsia e perspectiva no tratamento com o uso dos canabinóides

• Autor(a) principal: Medeiros, Elane Aparecida Pessoa de
• Data de Publicação: 2020
• Outros Autores: Vieira, Giovanna Custódio, Souza, Raquel Assunção de
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório do Centro Universitário Braz Cubas
• Texto Completo: https://repositorio.cruzeirodosul.edu.br/handle/123456789/1495
• topic: Epilepsia; Canabinóides; Cannabis; Canabidiol; Tetrahidrocanabinol; CNPQ::CIENCIAS DA SAUDE::FARMACIA

Epilepsy is defined as a chronic neurological disorder that causes abnormal electrical discharges and seizures. Social, behavioral, and economic impacts occur in 2-3% of the population. The proposed dichotomy for this condition is based on anticonvulsants, which most often manage to control crises. However, 30% are considered resistant to drugs, refractory to conventional abstinence since the anticonvulsants are not well-conditioned. Given the lack of therapeutic alternatives for the treatment of epilepsy, a plant belonging to the genus cannabis presents itself as an option in refractory cases because it contains more than 100 terpene phenolic compounds known as cannabinoids. Besides, many clinical studies show the beneficial effects of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), which are the most abundant active ingredients in the plant to control seizures. There is also the activity of modulating the crises obtained by the endocannabinoid system, which in refractory cases, causes total or partial improvement and, consequently, prevents brain damage. In addition, these cannabinoids cause toxic effects that are not relevant for a long time, nor is tolerance, dependence, or withdrawal.